Novo’s Rapid-acting Insulin Given FDA Approval

1963

On June 8, Novo Nordisk announced the Food and Drug Administration approved insulin aspart (NovoLog), its new rapid-acting insulin analogue.

According to Novo, NovoLog has faster absorption, faster onset of action and shorter duration of action than Regular human insulin, allowing people with diabetes to inject themselves immediately before eating.

“NovoLog will add the option of another fine Novo Nordisk product to the treatment choice for Americans with diabetes and will complement our range of therapeutics and medical devices such as NovoPen3,” said Bill Poole, president of Novo Nordisk.

NovoLog is sold as NovoRapid outside the United States Novo Nordisk received marketing approval for NovoRapid from the European Union last year, and it is now available in several European countries, including the United Kingdom and Germany.

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.